Citigroup Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $35

Seaport Therapeutics

Seaport Therapeutics

SPTX

0.00

Citigroup analyst Yigal Nochomovitz initiates coverage on Seaport Therapeutics (NASDAQ: SPTX) with a Buy rating and announces Price Target of $35.